Newlink Genetics Corporation (NASDAQ:NLNK) Reports Decline in Sellers; Strong Momentum for Longs

NewLink Genetics Corporation (NASDAQ:NLNK) Logo

Investors sentiment decreased to 0.82 in 2019 Q1. Its down 0.15, from 0.97 in 2018Q4. It dived, as 14 investors sold NewLink Genetics Corporation shares while 20 reduced holdings. 11 funds opened positions while 17 raised stakes. 12.32 million shares or 2.55% less from 12.64 million shares in 2018Q4 were reported.
26,613 were reported by Canada Pension Plan Invest Board. Bogle Mgmt Ltd Partnership De accumulated 0% or 23,047 shares. Tower Rech Capital Ltd Llc (Trc) invested in 0% or 7,181 shares. Parametric Portfolio Assocs Lc has invested 0% in NewLink Genetics Corporation (NASDAQ:NLNK). State Bank Of America De holds 0% of its portfolio in NewLink Genetics Corporation (NASDAQ:NLNK) for 200,765 shares. Fenimore Asset Management has invested 0% of its portfolio in NewLink Genetics Corporation (NASDAQ:NLNK). 345,918 were reported by Northern Tru Corporation. Geode Lc accumulated 487,981 shares. Federated Investors Inc Pa invested in 0% or 1,485 shares. New York-based Renaissance Technologies Lc has invested 0% in NewLink Genetics Corporation (NASDAQ:NLNK). Virtu Financial Lc holds 0% of its portfolio in NewLink Genetics Corporation (NASDAQ:NLNK) for 31,269 shares. Moreover, Deutsche Bancorporation Ag has 0% invested in NewLink Genetics Corporation (NASDAQ:NLNK). Alliancebernstein L P, New York-based fund reported 42,600 shares. Buckingham Asset Mgmt Limited Liability Corporation has invested 0% in NewLink Genetics Corporation (NASDAQ:NLNK). Northwestern Mutual Wealth Management Co holds 0% or 770 shares in its portfolio.

The stock of Newlink Genetics Corporation (NASDAQ:NLNK) registered a decrease of 4.42% in short interest. NLNK’s total short interest was 2.97 million shares in September as published by FINRA. Its down 4.42% from 3.10M shares, reported previously. With 371,100 shares average volume, it will take short sellers 8 days to cover their NLNK’s short positions. The short interest to Newlink Genetics Corporation’s float is 10.31%.

The stock increased 7.27% or $0.12 during the last trading session, reaching $1.77. About 182,083 shares traded. NewLink Genetics Corporation (NASDAQ:NLNK) has declined 52.80% since September 10, 2018 and is downtrending. It has underperformed by 52.80% the S&P500.

NewLink Genetics Corporation, a biopharmaceutical company, focuses on discovering, developing, and commercializing immunotherapeutic products for the treatment of cancer. The company has market cap of $65.64 million. The Company’s portfolio includes biologic product candidates based on its HyperAcute cellular immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells; and small-molecule product candidates that are focused on breaking the immune system's tolerance to cancer by inhibiting the indoleamine-2, 3-dioxygenase pathway and the tryptophan-2, 3-dioxygenase pathway. It currently has negative earnings. The firm is developing IDO pathway inhibitors comprising indoximod that is in multiple Phase I and Phase II clinical trials for patients with melanoma, pancreatic cancer, malignant brain tumors, metastatic breast cancer, acute myeloid leukemia, prostate cancer, and non-small cell lung cancer ; and GDC-0919 and atezolizumab (MPDL3280A) that is in Phase Ib clinical trials for patients with locally advanced or metastatic solid tumors.

More notable recent NewLink Genetics Corporation (NASDAQ:NLNK) news were published by: Globenewswire.com which released: “NewLink Genetics Presents Encouraging Phase 2 Results for NLG207 in Ovarian Cancer at AACR 2019 – GlobeNewswire” on April 02, 2019, also Globenewswire.com with their article: “NewLink Genetics to Participate in Upcoming Investor and Medical Conferences – GlobeNewswire” published on May 06, 2019, Seekingalpha.com published: “Healthcare names dominate midday movers – Seeking Alpha” on April 02, 2019. More interesting news about NewLink Genetics Corporation (NASDAQ:NLNK) were released by: Seekingalpha.com and their article: “WBA, EVOK and UGI among premarket losers – Seeking Alpha” published on April 02, 2019 as well as Globenewswire.com‘s news article titled: “NewLink Genetics to Host Its Fourth Quarter and Full Year 2018 Financial Results Conference Call on February 27, 2019 – GlobeNewswire” with publication date: February 07, 2019.

NewLink Genetics Corporation (NASDAQ:NLNK) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.